Price T Rowe Associates Inc. MD Cuts Stock Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Price T Rowe Associates Inc. MD lowered its position in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 12.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,104,037 shares of the medical equipment provider's stock after selling 151,611 shares during the period. Price T Rowe Associates Inc. MD owned about 1.59% of Lantheus worth $98,769,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in LNTH. Wilmington Savings Fund Society FSB acquired a new stake in shares of Lantheus in the 3rd quarter valued at approximately $25,000. Kestra Investment Management LLC acquired a new stake in Lantheus in the fourth quarter valued at $27,000. Summit Securities Group LLC purchased a new stake in shares of Lantheus during the 4th quarter worth $37,000. UMB Bank n.a. grew its stake in shares of Lantheus by 31.5% during the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock worth $50,000 after purchasing an additional 134 shares during the period. Finally, Parkside Financial Bank & Trust increased its holdings in shares of Lantheus by 49.4% in the 4th quarter. Parkside Financial Bank & Trust now owns 847 shares of the medical equipment provider's stock valued at $76,000 after purchasing an additional 280 shares in the last quarter. Hedge funds and other institutional investors own 99.06% of the company's stock.

Lantheus Stock Down 1.8 %

LNTH stock opened at $101.77 on Monday. Lantheus Holdings, Inc. has a 52 week low of $65.76 and a 52 week high of $126.89. The company has a market cap of $6.97 billion, a price-to-earnings ratio of 16.93 and a beta of 0.20. The business has a fifty day simple moving average of $97.37 and a 200-day simple moving average of $95.14.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.23). The firm had revenue of $391.11 million during the quarter, compared to analyst estimates of $376.61 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. As a group, analysts expect that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Mary Anne Heino sold 53,107 shares of the company's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the sale, the director now directly owns 440,399 shares of the company's stock, valued at approximately $41,551,645.65. This represents a 10.76 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the firm's stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $100.52, for a total value of $1,005,200.00. Following the completion of the transaction, the chief financial officer now directly owns 113,860 shares in the company, valued at $11,445,207.20. This trade represents a 8.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 63,109 shares of company stock worth $6,016,046 over the last ninety days. 1.50% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on LNTH. B. Riley lowered their target price on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating on the stock in a research report on Friday, March 21st. JMP Securities restated a "market outperform" rating and issued a $112.00 price target on shares of Lantheus in a report on Tuesday, January 14th. Finally, Truist Financial lifted their price objective on Lantheus from $120.00 to $127.00 and gave the stock a "buy" rating in a report on Thursday, February 27th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $129.43.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.